Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136539 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
A Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00136539: Completed Phase 2 study, sponsored by Harold J. Burstein, MD, PhD.
NCT00136539 is a Phase 2 study that has completed, run by Harold J. Burstein, MD, PhD. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136539, a Phase 2 study, has completed, sponsored by Harold J. Burstein, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
Interventions
- DRUG Cytoxan
- DRUG Taxol
- DRUG Adriamycin
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 1999-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136539
The ClinicalTrials.gov registry entry for NCT00136539 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harold J. Burstein, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cytoxan is the first listed.
NCT00136539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136539 about?
NCT00136539 is a clinical study titled "Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer". The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
What is the current status of trial NCT00136539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 1999-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00136539?
The interventions under investigation include: Cytoxan (DRUG), Taxol (DRUG), Adriamycin (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00136539?
This trial is sponsored by Harold J. Burstein, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.